

Date: June 22, 2023

The Deputy General Manager, Corporate Relationships Department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 SCRIP CODE: 524372	The Deputy General Manager, Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E) Mumbai – 400 051 SCRIP SYMBOL / SERIES: ORCHIDPHARMA
--	--

Dear Madam/Sir(s),

Sub: Qualified institutions placement of equity shares of face value ₹ 10 each (the “Equity Shares”) by Orchid Pharma Limited (the “Company”) under the provisions of Chapter VI of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”), and Sections 42 and 62 of the Companies Act, 2013, as amended, including the rules made thereunder (“Issue”)

Dear Sir/ Madam,

1. We wish to inform you that subsequent to the approval accorded by the board of directors of the Company (the “**Board**”), at its meeting held on December 01, 2022 and the special resolution passed by the shareholders of the Company on December 29, 2022, the Board has at its meeting held today i.e., June 22, 2023, *inter alia*, passed resolutions for the following:
 - a. Authorizing and declared the opening of the Issue today, i.e. June 22, 2023
 - b. Approved the floor price of ₹ 425.19 for the Issue, based on the pricing formula as prescribed under the SEBI ICDR Regulations; and
 - c. Approved and adopted the preliminary placement document dated June 22, 2023 and the application form dated June 22, 2023 in connection with the Issue (“**Preliminary Placement Document**”).
2. In relation to the Issue, we have filed the Preliminary Placement Document with your office on June 22, 2023, i.e., today.
3. We further wish to inform you that the ‘Relevant Date’ for the purpose of the Issue, in terms of the Regulation 171(a)(i) of the SEBI ICDR Regulations, is June 22, 2023 and accordingly the floor price in respect of the aforesaid Issue, based on the pricing formula as prescribed under Regulation 176(1) of the SEBI ICDR Regulations is ₹ 425.19 per Equity Share. Pursuant to the SEBI ICDR Regulations, the Company may offer a discount of not more than 5% on the floor price so calculated for the Issue.
4. In terms of Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“**SEBI LODR Regulations**”), we wish to inform you that a meeting of the Board of Directors is scheduled to be held on June 27, 2023 to, *inter alia*, consider and determine the issue price, including any discount, if any thereto permitted under SEBI ICDR Regulations for the Equity Shares to be allotted to qualified institutional buyers, pursuant to the Issue.

Trading Window Close:

Please note that the trading window will be closed with immediate effect until June 30, 2023 for the purpose of the Issue, in line with provisions of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended

The meeting of the Board of Directors commenced at 22.00 hours and concluded at 23.50 hours.

We request you to take the above on record and the same be treated as compliance under the applicable provisions of the SEBI LODR Regulations, as amended.

Thanking you,

Yours truly,
For **Orchid Pharma Limited**

Marina

Marina Peter
Company Secretary

